Myriad, AstraZeneca expand companion diagnostic agreement using BRACAnalysis CDx test

Myriad Genetics announced Wednesday the expansion of its companion diagnostic collaboration with AstraZeneca. Under the expanded agreement, Myriad's BRACAnalysis CDx test will be used in a Phase III trial to prospectively identify which patients with metastatic pancreatic cancer may respond to treatment with AstraZeneca's Lynparza (olaparib).

Mark Capone, president of Myriad Genetic Laboratories, remarked that "our collaboration with AstraZeneca is a big step forward in the fight against pancreatic cancer and in ensuring that personalised medicine becomes reality. BRACAnalysis CDx has the potential to quickly and accurately identify those patients who may be candidates for treatment with Lynparza and hopefully to accelerate better health outcomes."

In December 2014, the FDA cleared BRACAnalysis CDx to detect the presence of mutations in the BRCA genes in blood samples from patients with ovarian cancer who may be appropriate for treatment with Lynparza.

Did you like this article?